

Publikationen Dr. Manuela Licka, née Gehring

Licka M,..., Bauer A, Katus HA, Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required?

Herzschrittmacherther Elektrophysiol. 2011 Dec; 22(4): 209-13.

Connolly SJ, Camm AJ, Halperin JL...**Licka M** (Pallas Investigator)...Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76.

Connolly SJ, Eikelboom J, Joyner C...**Licka M** (Averroes Investigator)...Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17.

Bikou O*, **Licka M***, Kathoefer S, Katus HA, Bauer A. Cost savings and safety of ICD remote control by telephone: a prospective, observational study. J Telemed Telecare. 2010;16(7):403-8. (*: **equally contributed**).

Thomas D, Khalil M, Alter M...**Licka M**...,Zehelein,J, Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. J Mol Cell Cardiol. 2010 Jan;48(1):230-7.

Simon T, Becker R, Voss F...**Licka M**...,Bauer A, Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol. 2008 May;97(5):306-9.

Thomas D, Wimmer AB...**Licka M**...Zehelein J,. Dominant-negative I(Ks) suppression by KCNQ1-deltaF339 potassium channels linked to Romano-Ward syndrome. Cardiovasc Res. 2005 Aug 15;67(3):487-97.

Zehelein J, Thomas D, Khalil M...**Licka M**...Schoels W, Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome. Biochem Biophys Acta. 2004 Nov 5;1690(3):185-92.

Licka M, Zimmermann R, Zehelein J , ... Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002 Jun;87(6):520-4.

Bauer A, Schnabel PA, Schreiner KD...**Licka M**...Schoels W, Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall. Basic Res Cardiol. 2001 Apr;96(2):175-83.

Berthold F,SahinK,Hero B...**Gehring M** ...Terpe J, The current contribution of molecular factors to risk estimation in neuroblastoma patients. **Eur J Cancer**.1997 Oct;33(12):2092-7

Gehring M, Berthold F, Edler L, The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 1995 Nov 15;55(22):5366-9.

Corvi R, Amler LC, Savelyeva L, **Gehring, M**,.... MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5523-7.

Gehring M, Berthold F, Schwab M,... Genetic stability of microsatellites in human neuroblastomas. Int J Oncol. 1994 May;4(5):1043-5.

Kleihues P, Ohgaki H...**Gehring M**...Type and frequency of p53 mutations in tumors of the nervous system and its coverings. Recent Results Cancer Res. 1994;135:25-31.

Ohgaki H, Eibl RH...**Gehring M**...,Kleihues P, Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog.1993;8(2):74-80

Gehring M, Haag D., Goerttler K., Schwab M, Combined analysis of prognostic parameters in neuroblastoma, Clinical Chemistry and Enzymology Communications 1993;5(4-6):213-218

Takayama H, Suzuki T, **Gehring, M**, ...Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. *Oncogene*. 1992 Jun;7(6):1185-9.